Last Updated: 18 Sep 2024
Executive Summary
Ekso Bionics Holdings Inc. (EKSO) is a medical device company that designs, develops, sells, and rents exoskeleton products. The company has a market capitalization of $26.28 million and a beta of 1.46. The stock is currently trading at $1.22, which is below its 52-week high of $3.128 and above its 52-week low of $0.622.
Company Overview
Ekso Bionics was founded in 2005 and is headquartered in Richmond, California. The company's products are used to help people with mobility impairments walk, stand, and climb stairs. Ekso Bionics has a global sales force and its products are sold in over 40 countries.
Fundamental Analysis
Ekso Bionics reported revenue of $18.16 million in the first half of 2024, up 5.3% year-over-year. The company's gross profit margin was 37.2%, down from 41.3% in the first half of 2023. Ekso Bionics reported a net loss of $10.31 million in the first half of 2024, compared to a net loss of $10.63 million in the first half of 2023.
Ekso Bionics has a number of risks, including:
Competition from other medical device companies
Reimbursement challenges
Regulatory changes
Technical Analysis
The stock price of Ekso Bionics has been in a downtrend since early 2023. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is below 30, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for Ekso Bionics is negative. The stock is trading below its moving averages and the RSI is below 30. This indicates that the stock could continue to decline in the short term.
Long Term Outlook
The long-term outlook for Ekso Bionics is more positive. The company has a strong product portfolio and a global sales force. Ekso Bionics is also expanding into new markets, such as China. If the company can continue to execute on its growth strategy, it could be a good investment for long-term investors.
Analyst Recommendations
Two analysts have rated Ekso Bionics as a buy in the past 3 months. The average target price is $6.25. This indicates that analysts believe that the stock is undervalued and has the potential to appreciate in the long term.
